SCHEMBL10213929

SCHEMBL10213929

Nc1n[nH]c2ccc(-c3ccc4[nH]nc(N)c4c3)cc12

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 17/20 0.81
PDPK1 O15530 4/20 0.64
JAK3 P52333 4/20 0.64
TYK2 P29597 3/20 0.64
JAK1 P23458 1/20 0.64
PLK4 O00444 2/20 0.61
DAPK3 O43293 2/20 0.61
DYRK3 O43781 2/20 0.61
ROCK2 O75116 2/20 0.61
MAP4K4 O95819 2/20 0.61
CDK1 P06493 2/20 0.61
CDK2 P24941 2/20 0.61
MARK3 P27448 2/20 0.61
CLK2 P49760 2/20 0.61
CDK5 Q00535 2/20 0.61
PRKCD Q05655 2/20 0.61
ROCK1 Q13464 2/20 0.61
DYRK1A Q13627 2/20 0.61
PKN2 Q16513 2/20 0.61
MARK2 Q7KZI7 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12907246 0.90 JAK2 (1.00) JAK2PDPK1JAK3TYK2JAK1
SCHEMBL3359889 0.90 JAK2 (1.00) JAK2PDPK1JAK3TYK2JAK1
SCHEMBL12907187 0.89 JAK2 (0.72) JAK2PDPK1JAK3TYK2JAK1
SCHEMBL31690865 0.89 JAK2 (1.00) JAK2PDPK1JAK3TYK2JAK1
SCHEMBL12907171 0.89 JAK2 (0.72) JAK2PDPK1JAK3TYK2JAK1
SCHEMBL10213932 0.89 JAK2 (0.72) JAK2PDPK1JAK3TYK2JAK1
SCHEMBL10213923 0.86 JAK2 (0.65) JAK2PDPK1JAK3TYK2JAK1
SCHEMBL26886503 0.86 PDPK1 (0.74) JAK2PDPK1JAK3TYK2JAK1
SCHEMBL10213915 0.84 JAK2 (0.61) JAK2PDPK1JAK3TYK2JAK1
SCHEMBL22715912 0.84 JAK2 (0.71) JAK2PDPK1JAK3TYK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 JAK2 1822/4885PDPK1 856/4885JAK3 2399/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 JAK2 1822/4885PDPK1 856/4885JAK3 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.